Open Accelerator Announces Winning Life Science Start-Ups
News Jan 02, 2018
ZCube announces the winners of the second edition of its Open Accelerator programme aimed at Life Science start-ups and entirely supported by the Italian company: Zambon.
The winners and their awards are as follows:
- ANANAS LIVER: A drug delivery system for chronic hepatitis limiting undesired side-effects in patients – University of Padua – Award: 100,000 euro seed investment and access to Zambon’s campus: OpenZone;
- BIOREK: New diagnostic biomarkers and predictors of kidney cancer - San Raffaele Hospital, Milan – Award: 50,000 euro seed investment and access to Zambon’s campus: OpenZone;
- PD-INNOVATIONS: Integrated solution for Parkinson’s patients covering diagnosis and monitoring of symptoms as well as management of therapy – Bio-medical Campus of the University of Roma and the University of Oxford – Award: 25,000 euro seed investment and access to Zambons’ campus: OpenZone;
- PDMEE: Digital platform for real-time management of symptoms and non-motor symptoms of Parkinson’s disease, management of pharmaceutical therapy and tailoring of treatment to the individual – University of Padua - access to Zambons’ campus: OpenZone;
- GIMOpd: Tailored, efficient management of Parkinson’s disease based on patented neuroimaging integrated with biomarkers and movement analysis - Instituto de Biomedicina de Sevilla (IBiS) - access to Zambons’ campus: OpenZone.
ANANAS LIVER, BIOREK and PD-INNOVATIONS will also each benefit from consultancy services worth 5,000 euros provided by Deloitte Italy and 3 legal advisory consultations by the international firm Bird&Bird.
“With its second edition Open Accelerator has gone international and confirms its key role in providing concrete support to young researchers and entrepreneurs. It plays a key part in helping innovation in Life Science reach maturity by providing a high quality training programme that a network of highly qualified experts contributes to,” comments Elena Zambon, President at Zambon Spa. "We feel strongly that innovation should be rewarded and it’s with this objective in mind that Open Accelerator offers the winning start-ups an initial seed investment intended to help them take their first steps in the world of business.”
The call for ideas focused on four key areas: Drug delivery systems; Open source prototyping: medical devices, biomarkers, diagnostics; Wearables & digital health; and Big data. The call for ideas was launched in April 2017 and on closing, in early July 2017, 124 proposals had been submitted from across the globe. Further to careful selection, the most deserving projects were chosen and were able to take part in a 12 week acceleration programme that started in September. The programme was devised by Zcube in partnership with Deloitte’s Officine Innovazione, to provide researchers and scientists with the opportunity to work on their idea and/or prototype and develop a sustainable and profitable development strategy for their start-up’s business model.
“We innovate with passion and are committed to knowledge-sharing - explains Giovanni Rizzo, Chief of the Innovation Division, Zcube - via our accelerator programme we provide start-ups with a launch-pad into the Life Science sector.
The programme takes place at OpenZone, a scientific campus that houses Life Science businesses and represents the ideal environment to provide start-ups with the right level of support ranging from technology to business development.”
The programme features the support of over 150 mentors, advisors and international and national partners that include entrepreneurs, business angels, venture capitalists and experts from major businesses in addition to those representing the four partners of the accelerator: Unicredit Start Lab, Innogest, Italian Angel for Biotech (IAB) and the Gaetano Marzotto Award.
The panel examining the 13 finalist projects was composed as follows:
- Emil Abirashid, Chairman of the Selection Commettee Premio per l'Impresa, Premio Marzotto;
- Luca Benatti, CEO Erydel and President Italian Angels for Biotech (IAB);
- Simonetta Bocca, Global HR, Open Organization and Digital Strategy, Zambon Spa;
- Michele Gaiotto, Investment Strategy Analyst, Secofind;
- Claudio Giuliano, Managing Partner and Founder, Innogest;
- Lorenzo Leoni, Managing Partner, Ti Venture.
- Francesca Perrone, Head of Territorial and Sectorial Development Plans, Unicredit;
- Roberto Tascione, CEO, Zambon Spa and President Zcube;
- Alberto Trombetta, Head of Illiquid Investments Advisory, Gruppo Esperia;
- Elena Zambon President, Zambon Spa
‘Good Cholesterol’ May Not Always be Good for Postmenopausal WomenNews
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) – also known as ‘good cholesterol’ – according to a study led by researchers in the University of Pittsburgh Graduate School of Public Health.READ MORE
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.